pharmacovigilance

(redirected from Drug safety)
Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.

phar·ma·co·vi·gi·lance

(far'ă-kō-vij'ĭl-ănts),
The study of drug-related adverse effects carried out by pharmaceutical industries to suggest warnings or recommendations for product withdrawal.

pharmacovigilance

(1) A state of heightened awareness, monitoring and reporting of potentially adverse pharmacologic events.
(2) The branch of pharmacology focused on detecting, assessing, understanding and preventing long- and short-term adverse effects of medicines.

pharmacovigilance

(făr″mă-kō-vĭj′ĭ-lĭns) [″ + ″]
The analysis, detection, and prevention of adverse effects caused by medications.

pharmacovigilance,

n the monitoring of adverse effects of drugs and herbal remedies as they are used in the population. Also called
postmarketing surveillance.
References in periodicals archive ?
IDC Health Insights focuses on the following key criteria to define excellence in drug safety services:
Also calling for additional steps to address the drug safety crisis is Bill Vaughn, senior policy analyst for the Consumers Union.
The current organizational structure perpetuates the misperception that ensuring drug safety is solely the responsibility of the current Office of Drug Safety.
Secretary Leavitt said that the new board would resolve disagreements over approaches to drug safety issues, oversee development and implementation of center-wide drug safety policies, and assess the need for MedGuides.
The law required companies to demonstrate drug safety and efficacy by conducting well-controlled and properly recorded scientific experiments.
Management of strategic projects that provide insights into emerging drug safety and supporting regulatory compliance requirements
Klepper and the others at Drug Safety Navigator made sense at many levels.
There are risks associated with every product, and companies need mechanisms for drug safety surveillance," said Dr.
Seligman will provide oversight of drug safety issues and policies and manage the staff who disseminate safety information to healthcare professionals and patients through FDA's website.
Seligman will coordinate drug safety policy and risk communications, according to CDER director Dr.
The drug safety board is being touted as an independent entity, yet law-makers and consumer groups have questioned how much independence or authority the board will actually have.
Although the drug safety board is being touted as an independent entity, lawmakers and consumer groups have questioned how much independence or authority the board will actually have.